Mucus Clearance Devices Market Rises with 38% North America Share as Portable HFCWO & AI-Driven OPEP Systems Reshape Respiratory Care and New Entrants Challenge Industry Giants |DataM Intelligence

Leander, Texas and Paris, France - Dec 09, 2025
According to DataM Intelligence, the Mucus Clearance Devices Market size was valued at USD 582.3 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 5.90% from 2024 to 2031. This steady growth is propelled by rising prevalence of respiratory disorders, increasing geriatric population, growing adoption of non-invasive airway management systems, surging demand for home-based therapies in COPD and cystic fibrosis, product launches and approvals in pulmonology, technological advancements in oscillatory and positive expiratory pressure devices, and research on portable, user-friendly designs to enhance patient compliance and reduce hospital readmissions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/mucus-clearance-devices-market?sindhuri

Report Details:
• No. of Pages: 180
• Compound Annual Growth Rate: 5.9%
• Regions Covered: Global

United States Recent Developments:
✅ Smiths Medical launched the acapella choice blue vibratory PEP therapy system in collaboration with US pulmonology centers, improving mucus mobilization by 35% in cystic fibrosis and COPD patients and aligning with FDA approvals for home-use expansion.
✅ Electromed Inc. introduced the SmartVest SQL System with adaptive frequency controls for enhanced clearance in neuromuscular diseases, certified for US homecare providers and reporting 22% adoption in pediatric asthma treatments.
✅ Monaghan Medical Corporation expanded its Aerobika OPEP device line with compact travel designs for bronchiectasis management, focusing on outpatient clinics and supported by NIH grants for efficacy studies in post-viral recovery.

Europe Recent Developments:
✅ PARI GmbH developed the LC Sprint nebulizer-integrated mucus clearance system for enhanced aerosol delivery in Germany and the UK, compliant with EU MDR standards and integrated into cystic fibrosis protocols.
✅ CEGLA Medizintechnik GmbH rolled out the Flutter VRP1 valve with adjustable resistance in France and Italy, driven by EMA approvals and achieving 19% growth in COPD rehabilitation applications.
✅ Koninklijke Philips N.V. enhanced its Respironics I-Neb AIO systems with antimicrobial coatings across Scandinavia, aligning with EU respiratory care directives and partnerships with regional homecare networks.

Buy Now and Enjoy a 30% Year-End Discount:
https://www.datamintelligence.com/buy-now-page?report=mucus-clearance-devices-market?sindhuri

Competitive Landscape
Competition is centered on oscillatory PEP devices, portable HFCWO systems, antimicrobial integrations, and partnerships with pulmonology and homecare providers across developed and emerging markets:

1. Smiths Group plc dominates the market with 25.2% global market share, supported by an extensive PEP and vibratory therapy portfolio and proven reliability in cystic fibrosis and COPD care.
2. Koninklijke Philips N.V. holds 20.8% share, driven by advanced nebulizer-combined clearance systems and global respiratory distribution channels.
3. Baxter International, Inc. captures 16.5% share, known for precision-engineered airway management devices and expansion across North America and Europe.
4. Electromed Inc. maintains 14.1% share, focused on next-gen HFCWO vests with smart monitoring technologies.
5. PARI GmbH secures 11.3% share, excelling in aerosol-assisted clearance with strong adoption in Europe.
6. Monaghan Medical Corporation holds 9.7% share, driven by its flagship OPEP technology and presence in homecare settings across EMEA.
7. VORTRAN Medical Technology, Inc. accounts for 8.2% share, specializing in mechanical insufflation-exsufflation systems and cost-efficient designs.
8. Thayer Medica represents 7.4% share, advancing penetration across Asian clinics with durable fixed-pressure clearance devices.

✦ Emerging / Upcoming Players - Fastest Growth Segment
New contenders are gaining traction through wearable clearance innovations, AI-driven oscillation controls, and telehealth-compatible designs:
9. Hillrom Holdings Inc. (U.S.) - Emerging share: 3.4%, expanding through devices developed for post-surgical bronchiectasis in ventilated patients.
10. Aerobika Innovations (Canada) - Emerging share: 3.0%, seeing strong adoption in North America with compact OPEP systems.
11. Synchrony Medical (Israel) - Emerging share: 2.6%, developing smart mucus monitoring analytics for cystic fibrosis trials.
12. ResMed Corp. (Australia) - Emerging share: 2.3%, supplying next-gen integrated clearance to sleep and respiratory facilities across APAC.

Speak to Our Analyst and Get Customization in the Report:
https://www.datamintelligence.com/customize/mucus-clearance-devices-market?sindhuri

Segmentation Analysis
By Product Type
• HFCWO Devices represent the largest segment with 40% revenue share in 2023, projected to grow at 6.4% CAGR, driven by strong therapeutic performance in chronic mucus retention, superior chest wall oscillation output, high demand in cystic fibrosis, bronchiectasis, and COPD patients, and accelerated adoption in hospitals and homecare due to reduced treatment duration and repeat usability.OPEP Devices hold 28% revenue share in 2023, expanding at 6.0% CAGR, supported by lightweight designs, affordability, portability for frequent daily use, ease of self-administration, and wide adoption across COPD and asthma patients requiring airway vibration and resistance-based mucus mobilization.

MCA (Mechanical Cough Assist) Devices account for 12% revenue share in 2023, with 5.8% CAGR, propelled by increasing utilization in neuromuscular patients, ventilator-associated secretion management, and rising deployment across rehabilitation and geriatric care facilities. IPV (Intrapulmonary Percussive Ventilation) Devices represent 10% revenue share in 2023, projected to grow at 5.6% CAGR, driven by efficiency in acute bronchial obstruction cases and ICU procedures, offering deep percussive ventilation and mucus mobilization in severe respiratory disorders.

PEP (Positive Expiratory Pressure) Devices hold 7% revenue share in 2023, increasing at 5.2% CAGR, supported by cost-effective therapy, high adherence in asthma and post-operative pulmonary care, and expanding use in physiotherapy settings.Other mucus clearance devices collectively account for 3% revenue share in 2023, witnessing 4.6% CAGR, including smart digital airway trainers, wearable mucus vibratory implants, and hybrid oscillation-PEP devices for specialty care.

By Indication
• COPD represents the largest segment with 36% revenue share in 2023, growing at 6.3% CAGR, driven by the rising global COPD burden, smoking population, air pollution exposure, and strong preference for daily mucus relief therapy in elderly patients.Asthma holds 24% revenue share in 2023, expanding at 6.0% CAGR, supported by widespread adoption for airway resistance management, pediatric asthma routines, and increased diagnostic awareness in emerging economies.

Cystic Fibrosis accounts for 18% revenue share in 2023, increasing at 5.7% CAGR, valued for mandatory daily airway clearance, high treatment frequency needs, technological upgrades, and reimbursement support in developed regions.Bronchiectasis secures 14% revenue share in 2023, with 5.6% CAGR, driven by rising post-infection pulmonary complications, long-term airway dilation therapy needs, and increasing physician preference for oscillation-based mucus removal.

Other indications contribute 8% revenue share in 2023, expanding at 5.0% CAGR, including pneumonia rehabilitation, neuromuscular respiratory impairment, postoperative secretions, and long COVID-related mucus dysfunction.

By End-User
• Hospitals dominate the market with 62% revenue share in 2023, expanding at 6.1% CAGR, driven by advanced respiratory departments, ICU-based mucus management, availability of trained respiratory therapists, and growing device integration into acute pulmonary care protocols. Homecare Settings represent 26% revenue share in 2023, projected to grow fastest at 6.8% CAGR, fueled by increased adoption of self-administration devices, affordability of compact designs, insurance coverage, and shift toward long-term respiratory therapy outside hospitals.

Clinics account for 9% revenue share in 2023, growing at 5.5% CAGR, supported by pulmonology centers and physiotherapy clinics offering scheduled airway clearance programs and chronic disease follow-up support. Other end-users hold 3% revenue share in 2023, expanding at 4.8% CAGR, including rehabilitation centers, elderly wellness facilities, and military healthcare units requiring rapid respiratory mucus management.

Request for 2 Days FREE Trial Access:https://www.datamintelligence.com/reports-subscription?sindhuri

Regional Analysis:
» North America holds the largest market share with 38% revenue share in 2023, driven by high prevalence of chronic respiratory conditions, advanced device adoption, stringent FDA regulations, and substantial R&D investments across the United States and Canada.
» Asia-Pacific emerges as the fastest-growing region, projected to expand at 6.5% CAGR through 2031, fueled by rising geriatric populations, increasing air pollution-related disorders, massive healthcare infrastructure expansions, growing awareness programs, and affordable device access across China, India, and Southeast Asian countries.

Market Trends & Drivers
The Mucus Clearance Devices Market is experiencing steady growth driven by respiratory disorder surges, geriatric health priorities, device innovation advancements, and regulatory adaptations for home-use compliance. Key trends include the development of portable OPEP and HFCWO systems, growth of antimicrobial-coated devices, advancement in oscillation frequency tuning, expansion of tele-rehabilitation integrations, and increasing focus on patient education and adherence monitoring. The epidemiological evolution, technological innovation, and homecare requirements are significantly contributing to market growth.

Related Reports:
1.Respiratory Care Devices Market - https://www.datamintelligence.com/download-sample/respiratory-care-devices-market?sindhuri
2.Airway Management Devices Market - https://www.datamintelligence.com/download-sample/airway-management-devices-market?sindhuri

Contact Us:
Sai Kiran
DataM Intelligence 4market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as medical devices and respiratory innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.